Canada markets open in 4 hours 30 minutes

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4103+0.0025 (+0.61%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.4078
Open0.4290
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3958 - 0.4290
52 Week Range0.1200 - 0.7200
Volume786,526
Avg. Volume1,005,488
Market Cap130.089M
Beta (5Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0490
Earnings DateMay 31, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
    GlobeNewswire

    Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

    TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an agreement with the University of Health Sciences Antigua (“UHSA”) to collaborate on utilizing Revive’s novel psychedelic-assisted therapies and pioneering the clinical research and developme

  • Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
    GlobeNewswire

    Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

    TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that Derrick Welsh, COO of Psilocin Pharma Corp., a division of the Company, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. The corporate presentation

  • Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
    GlobeNewswire

    Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

    TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a memorandum of understanding dated June 7, 2021 with Supriya Lifescience Ltd. (“Supriya”), a specialty pharmaceutical company based in India, to pursue manufacturing of the API, conducting cli